Regentis Biomaterials Ltd. (NYSE American: RGNT) — as of 2026-11-01

Note on sourcing: The primary company-specific material available comes from a single press release [1], which should be read critically, as it was a paid marketing engagement — IBN (IBN.ai) disclosed it receives $30,000 per quarter for up to 180 days of coverage of RGNT [1]. Company claims (clinical, commercial, market sizing) are therefore promotional in origin and are corroborated below where the source itself states them. Background snapshots (market cap, sector) are from internal point-in-time records, not independently cited here.